Clinical Trial of an Aldose Reductase Inhibitor in Diabetic Neuropathy

A single-blind, nonrandomized, placebo crossover clinical trial of an aldose reductase inhibitor, Alresta-tin (AY 22, 284) was performed over a 4-mo period in nine patients with diabetic peripheral neuropathy. Most patients had subjective benefit, but objective measures of conduction were essentially unchanged. Substantial toxicity was evident, particularly photosensitive Skin rash.